Iconix Biosciences, Inc.
Iconix Biosciences has developed leading products and services that apply novel and proprietary genomic technologies to profile candidate drug compounds in early discovery through to preclinical development, leading to a better understanding of candidate drugs in a faster, more cost-effective manner. The toxicology community is embracing this approach to increase the accuracy, sensitivity and speed of toxicity testing. Changing this paradigm will significantly impact the failure rate of late-stage preclinical compounds and provide a compelling return on investment. Through strategic growth and research, the company has identified the factors and is creating the environment that will lead to a 'tipping point' in the pharmaceutical and biotechnology industries, such that toxicogenomics becomes a standard practice in the drug discovery and development process.
Fielden
Mark R
MR
Iconix Biosciences, Inc., Molecular and Investigative Toxicology, 325 E Middlefield Road, Mountain View, CA 94043, USA. mfielden@iconixbiosciences.com
Halbert
Donald N
DN
D000818:Animals; D004345:Drug Industry / Q000379:methods* / Q000639:trends; D023281:Genomics / Q000379:methods / Q000639:trends; D006801:Humans; D013678:Technology, Pharmaceutical / Q000379:methods / Q000639:trends; D043922:Toxicogenetics / Q000379:methods* / Q000639:trends